Evidence map›Paper›PMID 39473624›Full record

ArticleADMET & DMPK2024

Optimizing gefitinib nanoliposomes by Box-Behnken design and coating with chitosan: A sequential approach for enhanced drug delivery.

Seema Rohilla, Rajendra Awasthi, Ankur Rohilla, Sachin Kumar Singh, Dinesh Kumar Chellappan, Kamal Dua, Harish Dureja

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ADMET & DMPK, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Seema RohillaGeeta Institute of Pharmacy, Geeta University, Naultha, Panipat, Haryana, India.
Rajendra AwasthiDepartment of Pharmaceutical Sciences, School of Health Sciences & Technology, UPES, Dehradun, Uttarakhand, India.
Ankur RohillaDepartment of Pharmaceutical Sciences, Universal Group of Institutions, Dera Bassi, Mohali, Punjab, India.
Sachin Kumar SinghSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India.
Dinesh Kumar ChellappanDepartment of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur, Malaysia.
Kamal DuaDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW, Australia.
Harish DurejaFaculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Purpose: This study aimed to improve the stability and prolonged gefitinib release from the nanoliposomes. Experimental approach: Nanoliposomes were prepared by reverse-phase evaporation and optimized using Box-Behnken design to investigate the influence of sonication time ( Key results: Optimized nanoliposomes were quasi-spherical shaped, with a mean dimension of 93.2 nm and an encapsulation efficiency of 87.56±0.17 %. Surface decoration of the optimized batch was done using different concentrations of chitosan. The optimal chitosan concentration required to adorn the nanoliposome surface was 0.01 %. In comparison to unadorned nanoliposomes (82.16±0.65 %), adorned nanoliposomes (78.04±0.35 %) released the drug consistently over 24 h via Fickian diffusion. The IC Conclusion: The developed nanoliposomes may offer a new path for melanoma clinics.

Indexed as

Liposomespulmonary cancerresponse surface methodology

Identifiers

PMID39473624
PMCPMC11517515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.